Objective:Apatinib is a novel inhibitor of vascular endothelial growth factor receptor-2.The goal of this study was to evaluate overall survival(OS)after a combination of transarterial chemoembolization(TACE)and apatinib in patients with advanced hepatocellular carcinoma(HCC)and to identify the factors affecting patient survival.Methods:Fifty-one patients with advanced HCC who received TACE in combination with apatinib in our hospital from June 2015 to May 2017 were enrolled.The OS and progression-free survival(PFS)were calculated using the Kaplan-Meier method.The log-rank test and Cox regression model were used to determine the factors affecting OS.Results:The median OS and PFS of the patients were 15 months and 10 months,respectively.The 1-,2-,and 3-year survival rates were 64.7％,23.5％,and 1.8％,respectively.Univariate survival analysis showed that patients with Child-Pugh A(P=0.006),reduction rate of proper hepatic artery(P=0.016),hand-foot syndrome(P=0.005),secondary hypertension(P=0.050),and without ascites(P=0.010)had a better OS.Multivariate analysis showed that hand-foot syndrome(P=0.014),secondary hypertension(P=0.017),and reduction rate of proper hepatic artery(P=0.025)were independent predictors of better OS.Conclusion:TACE combined with apatinib is a promising treatment for advanced HCC.Hand-foot syndrome,secondary hypertension,and the reduction rate of proper hepatic artery were associated with a better OS.

Zi-yi LIU;Xue-feng KAN;Li-jie ZHANG;Joyman MAKAMURE;Qing LI;Dan ZHAO;Guo-feng ZHOU;Gan-sheng FENG;Chuan-sheng ZHENG;Bin LIANG

Department of Radiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Hubei Province Key Laboratory of Molecular Imaging,Wuhan 430022,China

当代医学科学(英文)

[1]Zi-yi LIU;Xue-feng KAN;Li-jie ZHANG;Joyman MAKAMURE;Qing LI;Dan ZHAO;Guo-feng ZHOU;Gan-sheng FENG;Chuan-sheng ZHENG;Bin LIANG-.Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma:Analysis of Survival and Prognostic Factors)[J].当代医学科学(英文),2022(05):1015-1021

Transarterial,Chemoembolization,Combined,Apatinib,Treatment,Advanced,Hepatocellular,Carcinoma,Analysis,Survival,Prognostic,Factors,Objective,novel,inhibitor,vascular,endothelial,growth,receptor,goal,this,study,was,evaluate,overall,survival,OS,after,combination,transarterial,chemoembolization,TACE,apatinib,patients,advanced,hepatocellular,carcinoma,HCC,identify,factors,affecting,Methods,Fifty,one,who,received,our,hospital,from,June,May,were,enrolled,progression,free,PFS,calculated,using,Kaplan,Meier,method,log,rank,test,Cox,regression,model,used,determine,Results,median,months,respectively,year,rates,Univariate,analysis,showed,that,Child,Pugh,reduction,proper,hepatic,artery,hand,foot,syndrome,secondary,hypertension,without,ascites,had,better,Multivariate,independent,predictors,Conclusion,combined,promising,treatment,Hand,associated

0.565164